Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 26, 2019
Previous Article Next Article

Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's disease

Author affiliations

Abstract

We have identified tryptophan-based selective nanomolar butyrylcholinesterase (BChE) inhibitors. They are defined according to their chemical modularity, novel binding mode revealed by five solved crystal structures with human BChE, low cytotoxicity, and predicted permeability of the blood–brain barrier. Altogether, these factors indicate their potential as unique lead compounds for symptomatic therapy against Alzheimer's disease.

Graphical abstract: Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's disease

Back to tab navigation

Supplementary files

Article information


Submitted
15 Feb 2019
Accepted
05 Mar 2019
First published
06 Mar 2019

Chem. Commun., 2019,55, 3765-3768
Article type
Communication

Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's disease

A. Meden, D. Knez, M. Jukič, X. Brazzolotto, M. Gršič, A. Pišlar, A. Zahirović, J. Kos, F. Nachon, J. Svete, S. Gobec and U. Grošelj, Chem. Commun., 2019, 55, 3765
DOI: 10.1039/C9CC01330J

Social activity

Search articles by author

Spotlight

Advertisements